Nasopharyngeal Cancer Pipeline Insight Report 2021: Comprehensive Insights for Approx 30 Companies and Pipeline Drugs -

·4 min read

The "Nasopharyngeal Cancer - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This "Nasopharyngeal Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.


This segment of the Nasopharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nasopharyngeal Cancer Emerging Drugs

Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.

Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.

Tislelizumab: BioGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.

Tabelecleucel: Atara Biotherapeutics Inc.

Tabelecleucel, tab-cel is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.

PDR001: Novartis Pharmaceuticals

PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body's own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.

Nasopharyngeal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different NASOPHARYNGEAL CANCER drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nasopharyngeal Cancer

There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.


This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

  • Oral

  • Subcutaneous

  • Intravenous

  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Bispecific Antibody

  • Peptides

  • Small molecule

  • Gene therapy

  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nasopharyngeal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasopharyngeal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasopharyngeal Cancer drugs.


  • Nasopharyngeal Cancer Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs


  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Key Questions Answered

  • How many companies are developing Nasopharyngeal Cancer drugs?

  • How many Nasopharyngeal Cancer drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasopharyngeal Cancer?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasopharyngeal Cancer therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Nasopharyngeal Cancer and their status?

  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Akeso Pharmaceuticals, Inc.

  • Atara biotherapeutics

  • BeiGene

  • Betta Pharmaceuticals Co., Ltd.

  • Bristol-Myers Squibb

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  • Hoffman La Roche

  • Incyte Corporation

  • innovent Biologics

  • Jiangsu HengRui Medicine Co., Ltd.

  • Klus Pharma

  • Merck Sharp & Dohme Corp.

  • Novartis Pharmaceuticals

  • Tessa Therapeutics

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting